The largest database of trusted experimental protocols

2 protocols using fc blocking antibody 2.4 g2

1

In situ Lung Neutrophil Infection Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols
In situ lung neutrophil infection was analyzed in mice on day 1 or 23 after infection with 5x106 CFU of the green fluorescent BCG strain Myc409 [7 (link)]. Freshly collected lungs were incubated overnight at 4°C in 4% paraformaldehyde, 10% sucrose (w/vol in PBS) and then immersed in 30% sucrose (w/vol in PBS) for 4 h. Lung tissue was snap frozen in OCT compound (CellPath, Powys, UK). 8 μm-thick lung sections collected on Superfrost Plus slides (Thermo Fischer Scientific) were air-dried and stored at -80°C. Cryosections were blocked for 30 min with Fc-blocking antibody 2.4 G2 (BD Biosciences), washed in PBS with 2% FCS and incubated overnight at 4°C with anti-Ly-6G (clone1A8), (BD Biosciences) followed by incubation with Alexa 594 conjugated anti-rat (Invitrogen) and anti CD3ε (145-2C11, APC conjugated, Miltenyi Biotec) for the localization of T cells and neutrophils. Slides were washed in PBS with 2% and mounted with Fluoromount-G (eBioscience) including DAPI. Images were captured with a confocal Leica TCS SP8 microscope.
+ Open protocol
+ Expand
2

Multiparametric Phenotyping of Splenocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Splenocytes were cultured in U-bottom 96-well plates (VWR) at 1 × 106 cells/200 μl of supplemented RPMI medium and incubated as described for antigen processing assays. Thereafter, cells were washed and incubated for 5 min at 4 °C with Fc blocking antibody (2.4G2) (BD Pharmingen) before stained for 20 min in the dark at 4 °C with saturating concentrations of surface-targeted antibodies and viability markers. Cells were fixed with Cytofix/Cytoperm kit (BD Biosciences), measured by FACS Fortessa (BD Biosciences) and analysed by FlowJo software (Tree Star, Ashland, OR). Dead cells were excluded using Zombie Yellow (Biolegend). Antibodies used as follows: CD3-APC (145-2c11, Biolegend), F4/80-AF700 (cat. MCA497A700, BioRad), LY6G/6C-APC-Cy7 (RB6-8C5, BD), NK1.1-BV421 (PK136, Biolegend), MHCII-BV711 (M5/114, BD), CD11c-BV785 (N418, Biolegend), CD11b-PE-Cy7 (M1/70, BD), CD45R/B220-V500 (RA3-6B2, BD), CD103-PE (2E7, Invitrogen), CD8-Percp-Cy5.5 (53–6.7, Biolegend) and CD317-BV650 (927, Biolegend).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!